SFI
MRSN

Susquehanna Fundamental Investments’s Mersana Therapeutics MRSN Stock Holding History

Susquehanna Fundamental Investments’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,674
Closed -$131K – 1171
2024
Q4 		$131K Buy
+3,674
New +$190K ﹤0.01% 1029
2024
Q2 		$620K Buy
12,348
+2,983
+32% +$216K 0.01% 647
2024
Q1 		$1.05M Buy
+9,365
New +$931K 0.05% 343

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Susquehanna Fundamental Investments's MRSN Position: Q1 2025 in Review

Susquehanna Fundamental Investments sold out of Mersana Therapeutics (MRSN) in Q1 2025, closing a stake of 3,674 shares — an estimated $131K sold.

Susquehanna Fundamental Investments first reported a position in MRSN in Q1 2024 and held it in 3 quarters. The position peaked at $1.05M in Q1 2024. 108 funds tracked by Wall St. Rank hold MRSN as of Q1 2025.

  • Susquehanna Fundamental Investments reported no remaining Mersana Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 3,674 Mersana Therapeutics shares in Q1 2025, an estimated $131K.
  • Susquehanna Fundamental Investments first reported a position in Mersana Therapeutics in Q1 2024 and held it in 3 quarters.
  • Susquehanna Fundamental Investments's Mersana Therapeutics position peaked at $1.05M in Q1 2024.
  • 108 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2025, filed 14 May 2025.